Studies where airflow is blocked in lung disease in smokers
Examines where and how airflow is limited in people with COPD, emphysema or asthma-COPD overlap.
Key facts
- Who runs it
- Gelb, Arthur F., M.D.
- Where
- Lakewood, United StatesSee the site
- Trial code
- Registry title
- Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap
- Status
- Recruiting
- People taking part
- 60 people, planned
- Started
- 1 Jan 2017
- Expected to end
- 1 Dec 2027
- Type of study
- Observational
- Treatments tested
- As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap
- Record updated
- 27 October 2023
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adult smokers or former smokers with COPD, emphysema or asthma-COPD overlap. They must have smoked more than 15 pack years.
- Age
- 30 Years or older
- Sex
- All sexes can join.
- Disease stage
- COPD, emphysema, or asthma-COPD overlap, with mild to severe airflow limitation when breathing out. COPD/bronchitis and bronchiectasis in smokers is also listed.
Main reasons for not taking part
- Non-smokers
- Any other lung diagnosis
- Pulmonary fibrosis
- Other lung or whole-body diagnosis
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- asthma- copd overlap
- emphysema in smokers with smoking history > 15 pack years
- COPD/ bronchitis and bronchiectasis in smokers with smoking history
- >15 pack years
Who cannot take part
- non smokers
- any other pulmonary diagnosis
- pulmonary fibrosis
Where in United States
- Arthur F Gelb MDLakewood, United StatesContact: Arthur F Gelb, MDTaking people
About the trial
What the trial wants to find out
The purpose of this cross-sectional, observational study is to evaluate the site and mechanism(s) for expiratory airflow limitation in chronic, treated, current or former smokers (>15 pack years) with COPD, Emphysema, and Asthma-COPD Overlap with mild to severe expiratory airflow limitation. Treatment may include short and long acting inhaled beta2agonists, short and long acting inhaled muscarinic receptor antagonists, inhaled and or oral corticosteroid, oral antibiotic, supplemental oxygen, and PDE type 4 inhibitor. In some cases, the patient may have had a history of asthma preceding the development of COPD (Asthma COPD Overlap).
The group in the trial
- COPD, Emphysema, Asthma-COPD Overlap
Based on clinical, pathologic, laboratory, physiologic and radiologic differences, patient groups can be described.
Treatment: As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap
- Plain-language title
- Studies where airflow is blocked in lung disease in smokersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 27 October 2023